U.S. Transdermal Drug Delivery System Market Size, Share & Trends Report

U.S. Transdermal Drug Delivery System Market Size, Share & Trends Analysis Report By Technology (Active, Passive), By Application (Hormone, Cardiovascular, Neurodegenerative, CNS, Pain Management), And Segment Forecasts, 2019 - 2026

  • Published Date: Nov, 2019
  • Base Year for Estimate: 2018
  • Report ID: GVR-4-68038-103-0
  • Format: Electronic (PDF)
  • Historical Data: 2015 - 2017
  • Number of Pages: 75

Table of Contents

Chapter 1. Methodology and Scope
                     1.1. Research Methodology
                     1.2. Research Scope & Assumptions
                     1.3. List of Data Sources
Chapter 2. Executive Summary
                     2.1. Market Summary, 2018
Chapter 3. U.S. Transdermal Drug Delivery System Market Variables, Trends & Scope
                     3.1. Market Segmentation & Scope
                     3.2. Market Driver Analysis
                     3.3. Market Restraint Analysis
                     3.4. SWOT Analysis, By Factor
                          3.4.1. Political
                          3.4.2. Economic
                          3.4.3. Technological
                     3.5. Industry Analysis - Porter’s
Chapter 4. U.S. Transdermal Drug Delivery System Market: Technology Estimates & Trend Analysis
                     4.1. Technology Movement Analysis & Market Share, 2018 & 2026
                     4.2. Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following Technology:
                          4.2.1. Active
                          4.2.2. Passive
                               4.2.2.1. Matrix
                               4.2.2.2. Reservoir
Chapter 5. U.S. Transdermal Drug Delivery System Market: Application Estimates & Trend Analysis
                     5.1. Application Movement Analysis & Market Share, 2018 & 2026
                     5.2. Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following Application
                          5.2.1. CNS
                               5.2.1.1. Nausea & Vomiting
                               5.2.1.2. ADHD
                          5.2.2. Pain Management
                          5.2.3. Hormone
                               5.2.3.1. Men
                               5.2.3.2. Women
                          5.2.4. Addiction Therapies
                          5.2.5. Cardiology
                               5.2.5.1. Hypertension
                               5.2.5.2. Angina
                          5.2.6. Neurodegenerative
                               5.2.6.1. Parkinson’s Disease
                               5.2.6.2. Alzheimer’s Disease
                          5.2.7. Urology
Chapter 6. Competitive Landscape
                     6.1. Company Profiles
                     6.2. Contract Development And Manufacturing Organization (CDMO)
                          6.2.1. AdhexPharma
                               6.2.1.1. Company overview
                               6.2.1.2. Product benchmarking
                               6.2.1.3. Strategic initiatives
                          6.2.2. The Tapemark Company
                               6.2.2.1. Company overview
                               6.2.2.2. Product benchmarking
                               6.2.2.3. Strategic initiatives
                          6.2.3. Tesa-Labtec
                               6.2.3.1. Company overview
                               6.2.3.2. Product benchmarking
                               6.2.3.3. Strategic initiatives
                          6.2.4. 3M
                               6.2.4.1. Company overview
                               6.2.4.2. Product benchmarking
                               6.2.4.3. Strategic initiatives
                     6.3. Commercial-stage Pharmaceutical Companies
                          6.3.1. Novartis AG
                               6.3.1.1. Company overview
                               6.3.1.2. Product benchmarking
                               6.3.1.3. Strategic initiatives
                          6.3.2. Johnson & Johnson (Janssen Pharmaceuticals)
                               6.3.2.1. Company overview
                               6.3.2.2. Product benchmarking
                               6.3.2.3. Strategic initiatives
                          6.3.3. Mylan Pharmaceuticals, Inc.
                               6.3.3.1. Company overview
                               6.3.3.2. Product benchmarking
                               6.3.3.3. Strategic initiatives
                          6.3.4. Boehringer Ingelheim GmbH
                               6.3.4.1. Company overview
                               6.3.4.2. Product benchmarking
                               6.3.4.3. Strategic initiatives
                          6.3.5. Watson Pharmaceuticals, Inc.
                               6.3.5.1. Company overview
                               6.3.5.2. Product benchmarking
                               6.3.5.3. Strategic initiatives
                          6.3.6. Noven Pharmaceuticals, Inc.
                               6.3.6.1. Company overview
                               6.3.6.2. Product benchmarking
                               6.3.6.3. Strategic initiatives
                          6.3.7. Teva Pharmaceutical Inc.
                               6.3.7.1. Company overview
                               6.3.7.2. Product benchmarking
                               6.3.7.3. Strategic initiatives
                          6.3.8. Bayer Healthcare Pharmaceuticals Inc.
                               6.3.8.1. Company overview
                               6.3.8.2. Product benchmarking
                               6.3.8.3. Strategic initiatives
                          6.3.9. Amneal Pharmaceuticals LLC
                               6.3.9.1. Company overview
                               6.3.9.2. Product benchmarking
                               6.3.9.3. Strategic initiatives
                          6.3.10. LTS Lohmann Therapie-Systeme AG
                               6.3.10.1. Company overview
                               6.3.10.2. Product benchmarking
                               6.3.10.3. Strategic initiatives
                     6.4. Clinical-stage Pharmaceutical Companies
                          6.4.1. Taho Pharmaceuticals Ltd
                               6.4.1.1. Company overview
                               6.4.1.2. Product benchmarking
                               6.4.1.3. Strategic initiatives
                          6.4.2. Corsair Pharma/United Therapeutics Corporation
                               6.4.2.1. Company overview
                               6.4.2.2. Product benchmarking
                               6.4.2.3. Strategic initiatives
                          6.4.3. TherapeuticsMD
                               6.4.3.1. Company overview
                               6.4.3.2. Product benchmarking
                               6.4.3.3. Strategic initiatives
                          6.4.4. Corium International
                               6.4.4.1. Company overview
                               6.4.4.2. Product benchmarking
                               6.4.4.3. Strategic initiatives



List of Figures

Fig. 1 U.S. transdermal drug delivery system market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Commodity flow analysis
Fig. 10 Market outlook (2018)
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Porter’s five forces analysis
Fig. 14 PESTLE analysis
Fig. 15 U.S. transdermal drug delivery system market: technology movement analysis
Fig. 16 U.S. transdermal drug delivery system market technology outlook: Key takeaways
Fig. 17 Active transdermal drug delivery system market, 2015 - 2026 (USD Billion)
Fig. 18 Passive transdermal drug delivery system market, 2015 - 2026 (USD Billion)
Fig. 19 Reservoir transdermal systems market, 2015 - 2026 (USD Billion)
Fig. 20 Matrix transdermal systems market, 2015 - 2026 (USD Billion)
Fig. 21 U.S. transdermal drug delivery system market: Application movement analysis
Fig. 22 Home infusion therapy market application outlook: Key takeaways
Fig. 23 CNS market, 2015 - 2026 (USD Billion)
Fig. 24 Attention deficit hyperactivity disorder market, 2015 - 2026 (USD Billion)
Fig. 25 Nausea & vomiting market, 2015 - 2026 (USD Billion)
Fig. 26 Pain management market, 2015 - 2026 (USD Billion)
Fig. 27 Hormone market, 2015 - 2026 (USD Billion)
Fig. 28 Men hormone market, 2015 - 2026 (USD Billion)
Fig. 29 Women hormone market, 2015 - 2026 (USD Billion)
Fig. 30 Addictive therapies market, 2015 - 2026 (USD Billion)
Fig. 31 Cardiology market, 2015 - 2026 (USD Billion)
Fig. 32 Hypertension market, 2015 - 2026 (USD Billion)
Fig. 33 Angina market, 2015 - 2026 (USD Billion)
Fig. 34 Neurodegenerative market, 2015 - 2026 (USD Billion)
Fig. 35 Parkinson’s disease market, 2015 - 2026 (USD Billion)
Fig. 36 Alzheimer’s disease market, 2015 - 2026 (USD Billion)
Fig. 37 Urology market, 2015 - 2026 (USD Billion)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself...

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.